No Data
No Data
[Brokerage Focus] Bocom International maintains a "buy" rating on Peijia Medical (09996), pointing out that "outflow restrictions" are the biggest short-term factor suppressing the stock price.
Golden Horse Financial News | BOC International issued research reports, stating that due to adjustments to the Hang Seng Composite SmallCap Index, Piaget Medical (09996) will be removed from the list of stocks eligible for trading via the Hong Kong Stock Connect starting from September 10th. Current market concerns mainly revolve around: 1) Worries on the fundamental side regarding the slowing growth rate of TAVI implants, intensified competition in the TAVI and neurointerventional industries, and central procurement; 2) Concerns on the trading and funding side about the impact on the company's stock price after the "outbound trading" of the Hong Kong Stock Connect. The bank believes that concerns about the fundamentals have been adequately reflected in the previous price corrections, and the main factor suppressing stock prices in the short term is the trading pressure after the "outbound trading". In addition, the bank believes that the market
PUYIN INTERNATIONAL: Maintains a "buy" rating on PEGA MEDICAL-B (09996) with a target price of 7.5 Hong Kong dollars.
Puyin International believes that the market pays more attention to the company's TAVI business and partially overlooks the exceptional performance of the company's neurointerventional business, failing to fully value the neurointerventional business and thus undervaluing the company.
Understand the mid-term performance of Peijia Medical (9996.HK) in 2024 in 90 seconds.
Recently, Peijia Medical Limited (9996.HK) has released its interim performance for the period ending June 30, 2024. To understand the specific performance, we will show you in a short video.
Peijia Medical Limited's (HKG:9996) 26% Share Price Surge Not Quite Adding Up
Achieva Medical Entered Into an Exclusive Distribution Agreement With NowYon Medical
Performance Highlights | Peja Medical (9996.HK) -B dual core leads growth, improved operational efficiency, with neurointerventional business turning losses into profits.
On the morning of August 26, Hong Kong's innovative medical instruments company Peijia Medical (9996.HK) held the 2024 interim performance conference to provide a detailed explanation of the company's mid-term performance. The following are the key points of Peijia Medical's 2024 interim performance: Steady revenue growth, the endoscopic business achieved a turnaround from loss to profit. Financial report data shows that in the face of a complex market environment and the dual challenges of changing policies, the company achieved a revenue of approximately 3.01 billion yuan (RMB, the same below) in the first half of the year, an increase of 33.9% year-on-year. The revenue showed a steady growth trend, further consolidating its leading position in the industry, laying a solid foundation for future development.
No Data
No Data